Centrum Medyczne Evimed

Warsaw, Masovian Voivodeship 02-625

3 studies enrolling now · 10 studies all time

What they study most

Atopic Dermatitis, Chronic Spontaneous Urticaria, Eczema, Moderate Psoriasis, Plaque Psoriasis, Psoriasis, Psoriasis (PsO), Severe Psoriasis

Studies at this site

• A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema — Recruiting now
• A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema — Recruiting now
• A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis — Enrolling by invitation
• Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis — Running, not enrolling
• A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 — Completed
• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) — Completed
• A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3) — Stopped early
• Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis — Completed
• A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria — Stopped early
• A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2) — Completed